Hyderabad-based pharma formulator manufacturing and exporting generic and branded-generic tablets, sachets, oral liquids and ophthalmic products, plus contract-manufacturing (CDMO) services for other pharma companies.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 602 | 493 | 415 | 348 | 23 | -22 | -52 | -65 | -227 |
| Borrowings | 1.3k | 1.3k | 326 | 359 | 379 | 377 | 376 | 384 | 397 |
| Other Liabilities | 431 | 432 | 532 | 543 | 658 | 579 | 580 | 588 | 567 |
| Total Liabilities | 2.3k | 2.2k | 1.3k | 1.3k | 1.1k | 950 | 921 | 924 | 753 |
| AssetsFixed Assets | 965 | 1.0k | 502 | 520 | 436 | 418 | 408 | 393 | 386 |
| CWIP | 122 | 89 | 60 | 40 | 21 | 21 | 17 | 21 | 18 |
| Investments | 3 | 86 | 199 | 199 | 199 | 168 | 168 | 168 | 181 |
| Other Assets | 1.2k | 990 | 529 | 507 | 421 | 343 | 328 | 342 | 170 |
| Total Assets | 2.3k | 2.2k | 1.3k | 1.3k | 1.1k | 950 | 921 | 924 | 753 |
| Line item | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 21 | 422 | 80 | 567 | 28 | 35 | -24 | -2 |
| Cash from Investing | -164 | -89 | -196 | 404 | -16 | -5 | 28 | -5 |
| Cash from Financing | 186 | -338 | 72 | -1.0k | -10 | -34 | -6 | 5 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -142 | 333 | -33 | 1.1k | 11 | 30 | -26 | -6 |
| FCF Margin | — | — | — | — | — | — | — | — |
For capital-heavy businesses (telecom, power, heavy manufacturing) reported profit ignores the cash needed just to stand still. We'd systematically overvalue it, so we don't show a number.
VIVIMEDLAB · CAPITAL_INTENSIVE
Guides on how to read this kind of business and the numbers that matter.